Oral Contraceptive DDI Study

Exclusion Criteria

• •History of any contraindications to the combined oral contraceptive tablet including thrombosis and the history of any thromboembolic disease, recurrent jaundice, acute or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding, significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or suspected)
• •Prior exposure to sotagliflozin (LX4211)
• •History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality
• •Concurrent conditions that could interfere with safety and/or tolerability measurements
• •Women who are breastfeeding or are planning to become pregnant during the study
• •Positive serum pregnancy test
• •Have taken injectable contraceptives or hormonal intrauterine devices within 12 months prior to the first dose of Period 1 or topical controlled delivery contraceptives (patch) for 3 months prior to the first dose of Period 1